AU2022234314A1 - Salt and solid forms of a kinase inhibitor - Google Patents

Salt and solid forms of a kinase inhibitor Download PDF

Info

Publication number
AU2022234314A1
AU2022234314A1 AU2022234314A AU2022234314A AU2022234314A1 AU 2022234314 A1 AU2022234314 A1 AU 2022234314A1 AU 2022234314 A AU2022234314 A AU 2022234314A AU 2022234314 A AU2022234314 A AU 2022234314A AU 2022234314 A1 AU2022234314 A1 AU 2022234314A1
Authority
AU
Australia
Prior art keywords
salt
compound
crystalline
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022234314A
Other languages
English (en)
Inventor
Erika BUTLER
Nimita Dave
Tuan DONG SI
Brian HEINRICH
Caitlin KINKEMA
Christopher Lee
Hui Li
Lauren MACEACHERN
Clare Aubrey Medendorp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AU2022234314A1 publication Critical patent/AU2022234314A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2022234314A 2021-03-10 2022-03-10 Salt and solid forms of a kinase inhibitor Pending AU2022234314A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163159107P 2021-03-10 2021-03-10
US63/159,107 2021-03-10
US202163208641P 2021-06-09 2021-06-09
US63/208,641 2021-06-09
PCT/US2022/019776 WO2022192558A1 (en) 2021-03-10 2022-03-10 Salt and solid forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
AU2022234314A1 true AU2022234314A1 (en) 2023-09-28

Family

ID=81074313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022234314A Pending AU2022234314A1 (en) 2021-03-10 2022-03-10 Salt and solid forms of a kinase inhibitor

Country Status (11)

Country Link
US (1) US20240254130A1 (https=)
EP (1) EP4305036A1 (https=)
JP (1) JP2024509276A (https=)
KR (1) KR20240013720A (https=)
AU (1) AU2022234314A1 (https=)
BR (1) BR112023018246A2 (https=)
CA (1) CA3211477A1 (https=)
CR (1) CR20230479A (https=)
IL (1) IL305791A (https=)
MX (1) MX2023010606A (https=)
WO (1) WO2022192558A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
WO2024171143A1 (en) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021020441A2 (pt) 2019-04-12 2021-12-14 Blueprint Medicines Corp Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra

Also Published As

Publication number Publication date
US20240254130A1 (en) 2024-08-01
EP4305036A1 (en) 2024-01-17
BR112023018246A2 (pt) 2024-01-30
JP2024509276A (ja) 2024-02-29
CA3211477A1 (en) 2022-09-15
MX2023010606A (es) 2023-10-19
KR20240013720A (ko) 2024-01-30
CR20230479A (es) 2024-03-08
WO2022192558A1 (en) 2022-09-15
IL305791A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US11999744B2 (en) Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
EP4359400B1 (en) Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer
AU2022234314A1 (en) Salt and solid forms of a kinase inhibitor
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
US11878980B2 (en) Solid forms of TTK inhibitor
WO2023215431A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
CN117794935A (zh) 激酶抑制剂的盐和固体形式
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
TW201211036A (en) Useful salts of indazole derivative
KR20220143666A (ko) 다환 역형성 림프종 키나아제 억제제의 결정형
TWI919884B (zh) 一種嘧啶并氮雜環類化合物的晶型及其製備方法及應用
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
TW202547508A (zh) 一種嘧啶并氮雜環類化合物的晶型及其製備方法及應用
CN120383595A (zh) 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物
HK40058236B (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
HK40058236A (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
HK40007702A (en) Solid forms of ttk inhibitor
HK40007702B (en) Solid forms of ttk inhibitor